← Back to Search

Behavioral Intervention

Nudge Communication for Flu Vaccination (KP-VACCINATE Trial)

N/A

Recruiting

Led By Natalia Berry, MD

Research Sponsored by Kaiser Permanente

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥18 years

Be older than 18 years old

Must not have

Unable to receive or opted out of receiving health system messaging

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is looking at how to increase flu vaccination rates among Kaiser Permanente members. Getting the flu shot can help reduce flu-related illnesses and hospitalizations, as well as potentially lower the risk of

Who is the study for?

This trial is for members of Kaiser Permanente in Northern California and the Mid Atlantic States who are eligible to receive an influenza vaccine. The study aims to see if special communication focused on heart health can increase flu shot rates.

What is being tested?

The trial is testing whether a cardiovascular-focused 'nudge' communication can boost influenza vaccination uptake compared to usual care messages during the flu season.

What are the potential side effects?

Since this trial involves communication strategies rather than medical treatments, there are no direct side effects from interventions like you would expect with drugs or surgeries.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot or chose not to receive messages from my healthcare provider.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of participants with documented influenza vaccine receipt

Secondary study objectives

Time to influenza vaccine receipt

Other study objectives

All Cause Resource Utilization

All-cause death

All-cause intensive care unit (ICU) days

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Usual Care/CV NudgeExperimental Treatment1 Intervention

Intervention arms will test the effects of a cardiovascular-focused nudge communication developed using behavioral economic principles. This arm will receive the usual care communication at first timepoint and then cardiovascular-focused nudge communication at the second timepoint during the influenza season.

Group II: CV Nudge/Usual CareExperimental Treatment1 Intervention

Intervention arms will test the effects of a cardiovascular-focused nudge communication developed using behavioral economic principles. This arm will receive the cardiovascular-focused nudge communication at first timepoint and then usual care communication at the second timepoint during the influenza season.

Group III: CV Nudge/CV NudgeExperimental Treatment1 Intervention

Intervention arms will test the effects of a cardiovascular-focused nudge communication developed using behavioral economic principles. This arm will receive the cardiovascular-focused nudge communication at 2 different timepoints during the influenza season.

Group IV: Usual Care/Usual CareActive Control1 Intervention

The usual care arm will receive standard-of-care communication encouraging vaccination at both timepoints during the influenza season.

0 / 2Eligibility criteria met